These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

652 related articles for article (PubMed ID: 33178682)

  • 1. Intracellular Alpha-Synuclein and Immune Cell Function.
    Grozdanov V; Danzer KM
    Front Cell Dev Biol; 2020; 8():562692. PubMed ID: 33178682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microglia Response During Parkinson's Disease: Alpha-Synuclein Intervention.
    Ferreira SA; Romero-Ramos M
    Front Cell Neurosci; 2018; 12():247. PubMed ID: 30127724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functions of Intracellular Alpha-Synuclein in Microglia: Implications for Parkinson's Disease Risk.
    Booms A; Coetzee GA
    Front Cell Neurosci; 2021; 15():759571. PubMed ID: 34671245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased Immune Activation by Pathologic α-Synuclein in Parkinson's Disease.
    Grozdanov V; Bousset L; Hoffmeister M; Bliederhaeuser C; Meier C; Madiona K; Pieri L; Kiechle M; McLean PJ; Kassubek J; Behrends C; Ludolph AC; Weishaupt JH; Melki R; Danzer KM
    Ann Neurol; 2019 Oct; 86(4):593-606. PubMed ID: 31343083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infiltrating T lymphocytes reduce myeloid phagocytosis activity in synucleinopathy model.
    Sommer A; Fadler T; Dorfmeister E; Hoffmann AC; Xiang W; Winner B; Prots I
    J Neuroinflammation; 2016 Jun; 13(1):174. PubMed ID: 27364890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intrastriatal injection of preformed alpha-synuclein fibrils alters central and peripheral immune cell profiles in non-transgenic mice.
    Earls RH; Menees KB; Chung J; Barber J; Gutekunst CA; Hazim MG; Lee JK
    J Neuroinflammation; 2019 Dec; 16(1):250. PubMed ID: 31796095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting of the class II transactivator attenuates inflammation and neurodegeneration in an alpha-synuclein model of Parkinson's disease.
    Williams GP; Schonhoff AM; Jurkuvenaite A; Thome AD; Standaert DG; Harms AS
    J Neuroinflammation; 2018 Aug; 15(1):244. PubMed ID: 30165873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NK cells clear α-synuclein and the depletion of NK cells exacerbates synuclein pathology in a mouse model of α-synucleinopathy.
    Earls RH; Menees KB; Chung J; Gutekunst CA; Lee HJ; Hazim MG; Rada B; Wood LB; Lee JK
    Proc Natl Acad Sci U S A; 2020 Jan; 117(3):1762-1771. PubMed ID: 31900358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The systemic immune response in Parkinson's disease: focus on the peripheral immune component.
    Lauritsen J; Romero-Ramos M
    Trends Neurosci; 2023 Oct; 46(10):863-878. PubMed ID: 37598092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting intracellular and extracellular alpha-synuclein as a therapeutic strategy in Parkinson's disease and other synucleinopathies.
    Vekrellis K; Stefanis L
    Expert Opin Ther Targets; 2012 Apr; 16(4):421-32. PubMed ID: 22480256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy in Parkinson's Disease: Micromanaging Alpha-Synuclein Aggregation.
    George S; Brundin P
    J Parkinsons Dis; 2015; 5(3):413-24. PubMed ID: 26406122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relation between α-synuclein and microglia in Parkinson's disease: Recent developments.
    Sanchez-Guajardo V; Tentillier N; Romero-Ramos M
    Neuroscience; 2015 Aug; 302():47-58. PubMed ID: 25684748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. α-Synuclein pathology in Parkinson's disease and related α-synucleinopathies.
    Henderson MX; Trojanowski JQ; Lee VM
    Neurosci Lett; 2019 Sep; 709():134316. PubMed ID: 31170426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic intranasal deferoxamine ameliorates motor defects and pathology in the α-synuclein rAAV Parkinson's model.
    Febbraro F; Andersen KJ; Sanchez-Guajardo V; Tentillier N; Romero-Ramos M
    Exp Neurol; 2013 Sep; 247():45-58. PubMed ID: 23531432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parkinson's disease: acid-glucocerebrosidase activity and alpha-synuclein clearance.
    Blanz J; Saftig P
    J Neurochem; 2016 Oct; 139 Suppl 1():198-215. PubMed ID: 26860955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glial α-synuclein promotes neurodegeneration characterized by a distinct transcriptional program in vivo.
    Olsen AL; Feany MB
    Glia; 2019 Oct; 67(10):1933-1957. PubMed ID: 31267577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure, function and toxicity of alpha-synuclein: the Bermuda triangle in synucleinopathies.
    Villar-Piqué A; Lopes da Fonseca T; Outeiro TF
    J Neurochem; 2016 Oct; 139 Suppl 1():240-255. PubMed ID: 26190401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. α-Synuclein and astrocytes: tracing the pathways from homeostasis to neurodegeneration in Lewy body disease.
    Sorrentino ZA; Giasson BI; Chakrabarty P
    Acta Neuropathol; 2019 Jul; 138(1):1-21. PubMed ID: 30798354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. α-Synuclein vaccination modulates regulatory T cell activation and microglia in the absence of brain pathology.
    Christiansen JR; Olesen MN; Otzen DE; Romero-Ramos M; Sanchez-Guajardo V
    J Neuroinflammation; 2016 Apr; 13(1):74. PubMed ID: 27055651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The yin and yang of α-synuclein-associated epigenetics in Parkinson's disease.
    Pavlou MAS; Pinho R; Paiva I; Outeiro TF
    Brain; 2017 Apr; 140(4):878-886. PubMed ID: 27585855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.